Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089

Redwood City, Calif., February 12, 2024 – Nuvig Therapeutics, Inc., (“Nuvig” or the “Company”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases today announced the first-in-human dosing of NVG-2089, a proprietary product being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune disease. Nuvig also announced… The post Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089 appeared first on Nuvig Therapeutics .